Ensartinib before surgery for ALK-positive lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how well the drug Ensartinib works when given before surgery to people with a certain type of lung cancer (ALK-positive NSCLC) that can be removed. The goal is to see if it helps shrink the tumor and is safe to take.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have non-small cell lung cancer that can be removed with surgery.
- Your cancer is stage II or III and has not spread too far.
- Your cancer has a specific gene change called ALK-positive, which must have been confirmed by a special test.
- You are planning to take Ensartinib as your only treatment before surgery for 6 to 12 weeks (if in Cohort 2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted therapy pill called ensartinib given before surgery for people with ALK-positive lung cancer. The goal is to see if it can shrink the tumor enough to make surgery more successful.
This trial tests an oral targeted therapy (Ensartinib) after surgery for patients with stage I ALK-positive lung cancer who have certain high-risk features. The goal is to see if it helps prevent cancer from returning.
This real-world study looks at how ensartinib works in people with advanced ALK-positive non-small cell lung cancer (NSCLC) whose disease has continued or worsened after ALK-targeted therapy. It may help doctors understand how well the treatment works and who benefits most in everyday care.
This trial tests whether the drug ensartinib can help prevent cancer from returning after standard chemoradiation in people with stage III ALK-mutated non-small cell lung cancer that cannot be removed by surgery. Enrolling those who have completed chemoradiation within the past 6 weeks without their cancer getting worse.
This trial tests lorlatinib as a treatment before surgery for people with a type of lung cancer called non-small cell lung cancer that has an ALK gene change (ALK-positive). The goal is to understand why some tumors respond and others may not, using advanced genetic tests.
This trial tests whether taking ensartinib before surgery can help people with a specific type of lung cancer that has the ALK gene change. It is for those whose cancer is stage II or III and can be surgically removed.
Hear when a new Ensartinib trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.